OriGene Logo

Customer Login

Checkout as a new customer

Creating an account has many benefits:

  • See order and shipping status
  • Track order history
  • Check out faster
Create an Account

TissueScan, Endometrial Cancer cDNA Array II

Be the first to review this product
SKU
EDRT102
48 samples covering 8-normal, 4-Stage IA, 4-IB, 4-IC, 2-IIA, 4-IIB, 1-II, 3-IIIA, 10-IIIC, 1-IVA, 3-IVB, 4-IV. Available in 2, 5, 10 identical plates.
  $1,060.00
2 Weeks*

Frequently Bought Together (4)

D11-18 Polink-1 HRP Polymer Detection for MOUSE and RABBIT antibodies on human tissue
18 ml
$420.00
D12-6 Polink-1 HRP Polymer Detection for MOUSE antibody on human or animal tissue (non-rodent)
6 ml
$250.00
HP205798 qSTAR qPCR primer pairs against Homo sapiens gene GAPDH 200 reactions
$150.00
MP205604 qSTAR qPCR primer pairs against Mus musculus gene Gapdh 200 reactions
$150.00
Specifications
Specifications
Product Data
TissueScan Type Cancer Specific
Array Name Endometrial Cancer cDNA Array II
Clinical Info
Diagnosis Category Endomentrial Cancer
Tissue Endometrium
Shipping Ambient
Description 48 samples covering 8-normal, 4-Stage IA, 4-IB, 4-IC, 2-IIA, 4-IIB, 1-II, 3-IIIA, 10-IIIC, 1-IVA, 3-IVB, 4-IV. Available in 2, 5, 10 identical plates.
Reviews
Write Review
 
 
 
 
 

Be the first to review this product

Please note:
Only reviews with images are eligible for a $20/20€ Amazon gift card.
Reviews without images are eligible for a $10/10€ Amazon gift card.
For more details about the terms and conditions, please visit the promotion page.

Review image
Documents
Resources

file-alt Citations

Alternative splicing of PBRM1 mediates resistance to PD-1 blockade therapy in renal cancer
Cho, Kim, Lee et al
EMBO J (2024)
Cited by 17
AI Summary: OriGene’s endometrial cancer cDNA array (EDRT102) and breast cancer cDNA array (BCRT101) were used in this study to validate alternative splicing patterns of PBRM1 exon 27 in cancer tissues.
Snippet: The endometrial cancer cDNA array, (ORIGENE, EDRT102) and the breast cancer cDNA array (ORIGENE, BCRT101) were used to validate the PBRM1 E27 AS patterns
Prognostic Relevance of Methylenetetrahydrofolate Reductase Polymorphisms for Prostate Cancer
Lin, Lu, Yin et al
Int J Mol Sci (2016) 17 (12) DOI: 10.3390/ijms17121996
AI Summary: OriGene's TissueScan human prostate cancer cDNA array II and III were used to measure MTHFR and ACTB (β-actin) expression levels in normal and prostate cancer tissue samples, enabling analysis of gene expression differences relevant to prostate cancer prognosis.
Snippet: The expression levels of MTHFR and ACTB (β-actin) were measured using the TissueScan human prostate cancer cDNA array II and III, including 17 normal and 79 prostate cancer samples (OriGene Technologies, Rockville, MD, USA)
FigureFigure
Inherited Variants in Wnt Pathway Genes Influence Outcomes of Prostate Cancer Patients Receiving Androgen Deprivation Therapy
Geng, Lin, Yu et al
Int J Mol Sci (2016) 17 (12) DOI: 10.3390/ijms17121970
AI Summary: OriGene’s TissueScan™ human prostate cancer cDNA array II was used to measure APC and β-actin expression levels in normal and prostate cancer tissue samples, helping to assess the relationship between APC gene variants and prostate cancer outcomes.
Snippet: The expression levels of APC and β-actin (ACTB) were measured using the TissueScan human prostate cancer cDNA array II, including 8 normal and 40 prostate cancer samples (OriGene Technologies, Rockville, MD, USA)
FigureFigureFigure
Beyond reduction of atherosclerosis: PON2 provides apoptosis resistance and stabilizes tumor cells
Witte, Altenhöfer, Wilgenbus et al
Cell Death Dis (2011) 2, e112 DOI: 10.1038/cddis.2010.91
Cited by 92
AI Summary: OriGene's TissueScan Cancer Survey Panel-III and Lymphoma Cancer Panel-II were used for quantitative real-time PCR analysis to assess PON2 expression levels in various tumor tissues in this study.
Snippet: 38 Given that high basal PON2 levels did not correlate with high sensitivity to its knock-down, future studies should test larger tumor ... tissues by quantitative real-time PCR using TissueScan Cancer Survey Panel-III (4 × 96-well format) and Lymphoma Cancer Panel-II (Origene).
FigureFigureFigure
Showing 1-4 of 4 papers.
Powered by BizGenius
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Related Products